UPDATE: JPMorgan Downgrades C4 Therapeutics (CCCC) to Neutral
Tweet Send to a Friend
(Updated - November 4, 2022 6:11 AM EDT)
JPMorgan analyst Eric Joseph downgraded C4 Therapeutics (NASDAQ: CCCC) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Eric Joseph downgraded C4 Therapeutics (NASDAQ: CCCC) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
